Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given
with standard of care treatment (maintenance temozolomide therapy). Study treatment will be
given until disease progression and patients will be followed for long-term survival
information. Efficacy will be measured by the progression-free survival status at 5.5 months
from the date of first dose.